Boyella VD, Nicastri AD, Bergasa NV

Language: Spanish
References: 23
Page: 221-225
PDF size: 139.94 Kb.

Text Extraction

Endogenous opioids participate in growth regulation. Liver regeneration relates to growth. Thus, we explored the expression of methionine enkephalin and of the delta opioid receptor 1 immunoreactivities with a polyclonal rabbit antibody in deparaffinized liver of patients with chronic liver disease. Fifteen of a total of fifty-eight samples expressed both opioid receptor and methionine enkephalin immunoreactivities, one sample expressed receptor but not methionine enkephalin immunoreactivity, and two samples expressed methionine enkephalin but not receptor immunoreactivity. Ten of the 45 (22%) samples from patients with chronic hepatitis C, four of the eight (50%) samples from patients with chronic hepatitis B, one of the five (20%) samples from patients with autoimmune hepatitis expressed both met-enkephalin and delta opioid receptor 1 immunoreactivities. The expression of methionine enkephalin and delta opioid receptor 1 immunoreactivities suggests that methionine enkephalin exerts an effect in situ, which may include regulation of liver regeneration. However, another possibility that concerns an effect of methionine enkephalin in the liver arises. As morphine, which acts via opioid receptors, has been reported to increase hepatitis C virus replication in vitro and to interfere with the antiviral effect of interferon, methionine enkephalin, analogous to morphine, may enhance the replication of the hepatitis C virus in the liver of patients with this type of viral hepatitis, and interfere with the therapeutic effect of interferon. These results may explain at least in part, why some patients with chronic hepatitis C infection do not respond to interferon therapy.

REFERENCES

1. Roskams T, de Vos R, Joost JVDO, Desmet V. Cells with neuroendocrine features in regenerating human liver. APMIS Suppl 1991; 23: 32-39.

2. Roskams T, van den Oord J, De Vos R, Desmet V. Neuroendocrine features of reactive bile ductules in cholestatic liver disease. Am J Pathol 1990; 13: 1019-1025.

3. Bergasa NV, Sabol SL, Young WSD, Kleiner DE, Jones EA. Cholestasis is associated with preproenkephalin mRNA expression in the adult rat liver. Am J Physiol 1995; 268: G346-354.

4. Bergasa NV, Liau S, Homel P, Ghali V. Hepatic Met-enkephalin immunoreactivity is enhanced in primary biliary cirrhosis. Liver 2002; 22: 107-113.

5. Nicoll J, Axiotis CA, Bergasa NV. The delta opioid receptor 1 is expressed by proliferating bile ductules in rats with cholestasis: implications for the study of liver regeneration and malignant transformation of biliary epithelium. Med Hypotheses 2005; 65: 1099-1105.

6. Marzioni M, Alpini G, Saccomanno S, de Minicis S, Glaser S, Francis H, Trozzi L, et al. Endogenous opioids modulate the growth of the biliary tree in the course of cholestasis. Gastroenterology 2006; 130: 1831-1847.

7. Zagon IS, Rhodes RE, McLaughlin PJ. Localization of enkephalin immunoreactivity in diverse tissues and cells of the developing and adult rat. Cell Tissue Res 1986; 246: 561-565.

8. Polakiewicz RD, Rosen H. Regulated expression of proenkephalin A during ontogenic development of mesenchymal derivative tissues. Mol Cell Biol 1990; 10: 736-742.

9. Rosen H, Bar-Shavit Z. Dual role of osteoblastic proenkephalin derived peptides in skeletal tissues. J Cell Biochem 1994; 55: 334-339.

10. McLaughlin PJ, Allar MA. Preproenkephalin gene expression and [Met5]-enkephalin levels in the developing rat heart. Brain Res Mol Brain Res 1998; 60: 160-167.

11. Zagon IS, Wu Y, McLaughlin PJ. Opioid growth factor and organ development in rat and human embryos. Brain Res 1999; 839: 313-322.

12. Marshall W. From cells on up: Symposium on Cell Biology of Development and Disease. EMBO Rep 2003; 4: 556-559.

13. Giannelli G, Quaranta V, Antonaci S. Tissue remodelling in liver diseases. Histol Histopathol 2003; 18: 1267-1274.

14. Fisher R. On the interpretation of X2 from contingency tables, and the calculation of P. J Royal Statist Soc 1922; 85: 87-94.

15. Lindley D. Regression and correlation analysis: New Palgrave, 1987.

16. Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Schmitt JM, Walker EC, et al. Naloxone ameliorates the pruritus of cholestasis: results of a double-blind randomized placebo-controlled trial. Annals of Internal Medicine 1995; 123: 161-167.

17. Zagon IS, Roesener CD, Verderame MF, Ohlsson-Wilhelm BM, Levin RJ, McLaughlin PJ. Opioid growth factor regulates the cell cycle of human neoplasias. Int J Oncol 2000; 17: 1053-1061.

18. Zagon IS, Verderame MF, Hankins J, McLaughlin PJ. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells. Int J Oncol 2007; 30: 775-783.

19. Li Y, Zhang T, Douglas SD, Lai JP, Xiao WD, Pleasure DE, Ho WZ. Morphine enhances hepatitis C virus (HCV) replicon expression. Am J Pathol 2003; 163: 1167-1175.

20. Kapas S, Purbrick A, Hinson JP. Action of opioid peptides on the rat adrenal cortex: stimulation of steroid secretion through a specific mu opioid receptor. J Endocrinol 1995; 144: 503-510.

21. Alt A, Mansour A, Akil H, Medzihradsky F, Traynor JR, Woods JH. Stimulation of guanosine-5'-O-(3-[35S]thio)triphosphate binding by endogenous opioids acting at a cloned mu receptor. J Pharmacol Exp Ther 1998; 286: 282-288.

22. Bergasa NV, Boyella VD. Liver derived endogenous opioids may interfere with the therapeutic effect of interferon in chronic hepatitis C. Medical Hypotheses 2008;70:556-9 .

23. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology 2006; 44: 1675-1684.